NHS Blood and Transplant

NHSBT is dedicated to saving and improving lives. Our Cellular and Molecular Therapies (CMT) function does this by offering experience and expertise in cell and gene therapy manufacturing from our national network of GMP-grade and MHRA-licensed facilities.

NHSBT is dedicated to saving and improving lives. Our Cellular and Molecular Therapies (CMT) function does this by offering experience and expertise in cell and gene therapy manufacturing from our national network of GMP-grade and MHRA-licensed facilities. The Clinical Biotechnology Centre (CBC), part of CMT, has more than 20 years’ experience manufacturing plasmids. Our new purpose-built facility in Filton, Bristol opened in 2023, increasing capacity for manufacture of GMP plasmids, viral vectors (AAV and lentiviral) and recombinant protein. CBC is also one of three MRC/LifeArc-funded Innovation Hubs for Gene Therapies, introduced to accelerate academic-led development of novel gene therapies throughout the UK. Operating on a ‘not-for-profit’ basis, NHSBT partners with academic, commercial and NHS organisations engaged in novel cell and gene therapy programmes, supporting concepts through to clinical trials. We welcome expressions of interest for contract projects, partnerships and joint grant proposals with organisations striving to develop the future of medicine in the advanced therapies space. Contact us: [email protected] https://www.nhsbt.nhs.uk/cmt